Intravenous bolus topotecan in patients with myelodysplastic syndrome.
We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.
Seiter
K
K
Zalmen A. Arlin Cancer Institute, Department of Medicine, New York Medical College, Valhalla 10595, USA. Karen_Seiter@NYMC.edu
Liu
D
D
Feldman
E J
EJ
Siddiqui
A D
AD
Hoang
A
A
Baskind
P
P
Kancherla
R
R
Ahmed
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy*; D012074:Remission Induction; D015996:Survival Rate; D013997:Time Factors; D019772:Topotecan / Q000008:administration & dosage* / Q000633:toxicity; D016896:Treatment Outcome
D019772:Topotecan